Abstract
In the previous study, one of the authors proposed a method to evaluate the serum antimycobacterial activity. By this method, however, the activity of CS and EB in sera from patients who had received a usual single dose of CS 250mg or EB 500 mg was not detected. Recently, clinical results of treatment with these drugs including the sputum culture negative conversion rate and the emergence of resistant organism have been obtained. The purpose of this study is to determine the criteria of clinical resistance to these drugs based on the relation between the serum antimycobacterial activity and the emergence of resistant organisms.
